Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novo Nordisk A/S (NYSE:NVO)

55.44
Delayed Data
As of May 27
 -0.61 / -1.09%
Today’s Change
46.17
Today|||52-Week Range
60.34
-4.55%
Year-to-Date
3 Stocks Underperforming Today In The Drugs Industry
May 26 / TheStreet.com - Paid Partner Content
Sanofi Diabetes Drugs Briefing Documents Raise Concerns
May 24 / Zacks.com - Paid Partner Content
Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
May 26 / Zacks.com - Paid Partner Content
Businesses That Win Trait No. 3: Long-Term Thinking
May 24 / MotleyFool.com - Paid Partner Content
Novo Nordisk IDegLira Recommended by FDA Advisory Committee
May 25 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close56.05
Today’s open55.44
Day’s range55.29 - 55.74
Volume1,364,315
Average volume (3 months)1,496,050
Market cap$108.7B
Dividend yield1.73%
Data as of 4:02pm ET, 05/27/2016

Growth & Valuation

Earnings growth (last year)+12.05%
Earnings growth (this year)--
Earnings growth (next 5 years)+12.35%
Revenue growth (last year)+1.43%
P/E ratio4.1
Price/Sales9.38
Price/Book20.66

Competitors

 Today’s
change
Today’s
% change
SNYSanofi+0.15+0.36%
GSKGlaxoSmithKline-0.34-0.79%
ABBVAbbVie+0.81+1.31%
BMYBristol-Myers Squibb+0.58+0.82%
Data as of 4:02pm ET, 05/27/2016

Financials

Next reporting dateAugust 5, 2016
EPS forecast (this quarter)$0.59
Annual revenue (last year)$16.0B
Annual profit (last year)$5.2B
Net profit margin32.30%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
President &
Chief Executive Officer
Lars Rebien Sørensen
Chief Financial Officer &
Executive Vice President
Jesper Brandgaard
Corporate headquarters
Bagsværd, Capital Region

Forecasts

Partner Offers

Search for Jobs